Chronic treatment with the antipsychotic drug blonanserin modulates the responsiveness to acute stress with anatomical selectivity
Sign Up to like & getrecommendations! Published in 2020 at "Psychopharmacology"
DOI: 10.1007/s00213-020-05498-9
Abstract: Rationale Patients diagnosed with schizophrenia typically receive life-long treatments with antipsychotic drugs (APDs). However, the impact of chronic APDs treatment on neuroplastic mechanisms in the brain remains largely elusive. Objective Here, we focused on blonanserin,… read more here.
Keywords: chronic treatment; treatment; blonanserin modulates; drug ... See more keywords
Experimental analysis of the onset mechanism of TdP reported in an LQT3 patient during pharmacological treatment with serotonin–dopamine antagonists against insomnia and nocturnal delirium
Sign Up to like & getrecommendations! Published in 2019 at "Heart and Vessels"
DOI: 10.1007/s00380-019-01521-y
Abstract: Torsade de pointes (TdP) occurred in a long QT syndrome type 3 (LQT3) patient after switching perospirone to blonanserin. We studied how their electropharmacological effects had induced TdP in the LQT3 patient. Perospirone hydrochloride (… read more here.
Keywords: heart; perospirone; tdp; total peripheral ... See more keywords
Lack of dopamine supersensitivity in rats after chronic administration of blonanserin: Comparison with haloperidol
Sign Up to like & getrecommendations! Published in 2018 at "European Journal of Pharmacology"
DOI: 10.1016/j.ejphar.2018.04.014
Abstract: Abstract Long‐term treatment with antipsychotic drugs in patients with schizophrenia can lead to dopamine supersensitivity psychosis. It is reported that repeated administration of haloperidol caused dopamine supersensitivity in rats. Blonanserin is an atypical antipsychotic drug… read more here.
Keywords: chronic administration; blonanserin; dopamine supersensitivity; dopamine ... See more keywords
Safety and effectiveness of oral blonanserin for schizophrenia: A review of Japanese post-marketing surveillances.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of pharmacological sciences"
DOI: 10.1016/j.jphs.2020.09.006
Abstract: Schizophrenia significantly limits social functioning with positive and negative symptoms and cognitive dysfunction. Blonanserin (LONASEN®), a novel second-generation antipsychotic approved for treating schizophrenia in Japan in 2008, reportedly shows beneficial effects on cognitive function as… read more here.
Keywords: schizophrenia; japanese post; post marketing; blonanserin ... See more keywords
Effectiveness and safety of blonanserin for improving social and cognitive functions in patients with first-episode schizophrenia: a study protocol for a prospective, multicentre, single-arm clinical trial
Sign Up to like & getrecommendations! Published in 2022 at "BMJ Open"
DOI: 10.1136/bmjopen-2021-054079
Abstract: Introduction Both the pharmacological characteristics of blonanserin and its related small sample size studies suggest that blonanserin could alleviate social and cognitive dysfunctions in patients with schizophrenia. However, no large sample size studies have been… read more here.
Keywords: blonanserin; episode schizophrenia; first episode; social cognitive ... See more keywords
The Influence of Blonanserin Supersaturation in Liquid and Silica Stabilised Self-Nanoemulsifying Drug Delivery Systems on In Vitro Solubilisation
Sign Up to like & getrecommendations! Published in 2023 at "Pharmaceutics"
DOI: 10.3390/pharmaceutics15010284
Abstract: Reformulating poorly water-soluble drugs as supersaturated lipid-based formulations achieves higher drug loading and potentially improves solubilisation and bioavailability. However, for the weak base blonanserin, silica solidified supersaturated lipid-based formulations have demonstrated reduced in vitro solubilisation… read more here.
Keywords: blonanserin; solubilisation; liquid; super snedds ... See more keywords